University Hospital Cologne-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2019

  1. Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations

    JCO Precision Oncology

2017

  1. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    The Lancet, Vol. 389, Núm. 10072, pp. 917-929